VRXA — Veraxa Biotech AG - Post de-SPAC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2079109 ·
Switzerland
Last close
$1.37
Market Cap
$193.73M
52W High
$27.36
52W Low
$1.27
ADV30
288,083
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 80,820,364 | 1,613,989 | 96,586,511 |
| Jun 2025 | — | — | — | — | 82,248,288 | 3,315,409 | 69,521,680 |
| Dec 2024 | — | — | — | — | 84,766,624 | 5,362,638 | 53,711,808 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-98,478,340
Inventory
—
Receivables
$1,170,351
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$23,426
EBITDA
$-64,244,176
Free Cash Flow
$15,751,170
Enterprise Value
—
Total Cash
—
Total Debt
—
Shares Out
141,407,813
Trailing EPS
$-0.58
Book Value
$-1.31
ROE
-871.4%
ROA
-50.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 23,426 | -66,216,575 | -66,613,990 | 80,820,364 | 96,586,511 | -15,766,147 | -9,902,331 |
| Dec 2024 | 0 | -28,917,881 | -28,132,971 | 84,766,624 | 53,711,808 | 31,054,816 | -7,720,393 |
| Dec 2023 | 0 | -16,659,993 | -16,544,238 | 91,936,907 | 36,809,163 | 55,127,744 | -7,267,818 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALXO | ALX ONCOLOGY HOLDINGS INC | $192.21M | $1.39 | — |
| NKTX | Nkarta, Inc. | $191.24M | $2.67 | — |
| ORMP | ORAMED PHARMACEUTICALS INC. | $197.59M | $4.75 | — |
| ANTX | AN2 Therapeutics, Inc. | $189.06M | $5.01 | — |
| CUE | Cue Biopharma, Inc. | $199.41M | $27.45 | — |
News headlines (Yahoo Finance, 1h cache)
VERAXA Biotech (VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase
2026-09-22 18:30 · Yahoo
VERAXA Biotech (VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progress
2026-09-24 19:38 · Yahoo
VERAXA Biotech (VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline
2026-09-18 19:30 · Yahoo
VERAXA Biotech (VRXA) Building a New Approach to Precision Cancer Therapy
2026-09-16 19:00 · Yahoo
VERAXA Biotech Designates Raju Willener as CFO
2026-09-09 15:46 · Yahoo
VERAXA Biotech (VRXA) Appoints Raju Willener as Chief Financial Officer
2026-09-08 18:34 · Yahoo
VERAXA Biotech (VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies
2026-08-06 18:30 · Yahoo
VERAXA Biotech (VRXA) Shareholders Approve Corporate Governance, Financing Measures
2026-07-28 17:45 · Yahoo
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
2026-07-27 11:00 · Yahoo
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
2026-07-23 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.